Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium - PubMed (original) (raw)
. 1989 Mar;35(3):295-303.
Affiliations
- PMID: 2564629
Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium
M R Bristow et al. Mol Pharmacol. 1989 Mar.
Abstract
Prenalterol (beta 1-agonist), denopamine (beta 1-agonist), and zinterol (beta 2-agonist) were partial agonists of adenylate cyclase (AC) stimulation in human ventricular myocardium obtained from nonfailing chambers whose beta 1/beta 2 receptor subtype ratio was approximately 80/20. At a concentration less than its low affinity (beta 2) Kl, betaxolol, a highly selective beta 1-antagonist, inhibited isoproterenol (non-selective agonist), denopamine, and prenalterol stimulation of AC, indicating that isoproterenol, denopamine, and prenalterol are all capable of stimulating AC through beta 1-receptor activation. At a concentration less than its low affinity (beta 1) Kl, ICI 118,551, a highly selective beta 2-agonist, inhibited both isoproterenol and zinterol stimulation of AC, indicating that isoproterenol and zinterol stimulate AC through beta 2-receptors. Zinterol stimulation of AC was mediated entirely by beta 2-receptors, inasmuch as 10(-7) M betaxolol had no effect on the zinterol dose-response curve and ICI 118,551 produced a degree of blockade (KB = 5.2 +/- 1.6 X 10(-9) M), consistent with the beta 2-receptor Kl of the latter (2.0 +/- .4 X 10(-9) M, p, not significant). In nonfailing myocardium, analysis of beta 1 versus beta 2 stimulation by the nonselective agonist isoproterenol revealed that the numerically small (19% of the total) beta 2 fraction accounted for the majority of the total adenylate cyclase stimulation. In failing ventricular chambers with a beta 1/beta 2 receptor subtype ratio reduced from 82/19 (nonfailing) to 64/36 (p less than 0.001) and a beta 1-receptor density reduced by 61% (p less than 0.001), maximal denopamine stimulation was reduced by 49% (p less than 0.001). Moreover, in preparations from failing heart, the component of denopamine stimulation that was inhibited by 10(-7) M betaxolol (beta 1 component) was reduced by 77% (p less than 0.05). Finally, in preparations derived from failing ventricular myocardium, beta 2-receptor density was not significantly decreased, but zinterol stimulation of AC was reduced by 32% (p less than 0.05). We conclude that heart failure results in subsensitivity to both selective beta 1 and beta 2 stimulation of adenylate cyclase, with beta 1 subsensitivity due to selective beta 1 receptor down-regulation and beta 2 subsensitivity due to partial uncoupling of beta 2 receptors from subsequent events in the beta 2-adrenergic pathway.
Similar articles
- Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, et al. Bristow MR, et al. Circ Res. 1986 Sep;59(3):297-309. doi: 10.1161/01.res.59.3.297. Circ Res. 1986. PMID: 2876788 - Beta 1-adrenergic selectivity of the new cardiotonic agent denopamine in its stimulating effects on adenylate cyclase.
Inamasu M, Totsuka T, Ikeo T, Nagao T, Takeyama S. Inamasu M, et al. Biochem Pharmacol. 1987 Jun 15;36(12):1947-54. doi: 10.1016/0006-2952(87)90493-x. Biochem Pharmacol. 1987. PMID: 3036156 - Beta-2 adrenergic activation of L-type Ca++ current in cardiac myocytes.
Skeberdis VA, Jurevicius J, Fischmeister aR. Skeberdis VA, et al. J Pharmacol Exp Ther. 1997 Nov;283(2):452-61. J Pharmacol Exp Ther. 1997. PMID: 9353357 - Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium.
Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. Bristow MR, et al. Circulation. 1990 Aug;82(2 Suppl):I12-25. Circulation. 1990. PMID: 2164894 Review. - beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy.
Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Gilbert EM, et al. Am J Cardiol. 1993 Mar 25;71(9):23C-29C. doi: 10.1016/0002-9149(93)90083-o. Am J Cardiol. 1993. PMID: 8096672 Review.
Cited by
- Cardiac contraction and relaxation are regulated by distinct subcellular cAMP pools.
Lin TY, Mai QN, Zhang H, Wilson E, Chien HC, Yee SW, Giacomini KM, Olgin JE, Irannejad R. Lin TY, et al. Nat Chem Biol. 2024 Jan;20(1):62-73. doi: 10.1038/s41589-023-01381-8. Epub 2023 Jul 20. Nat Chem Biol. 2024. PMID: 37474759 Free PMC article. - Passing the βAR: PI3Kγ Is the Judge of β Adrenergic Receptor Resensitization.
Quiles JM, Gustafsson ÅB. Quiles JM, et al. Circ Res. 2023 Mar 17;132(6):704-706. doi: 10.1161/CIRCRESAHA.123.322554. Epub 2023 Mar 16. Circ Res. 2023. PMID: 36927178 Free PMC article. No abstract available. - Pathophysiology and pharmacology of G protein-coupled receptors in the heart.
Grogan A, Lucero EY, Jiang H, Rockman HA. Grogan A, et al. Cardiovasc Res. 2023 May 22;119(5):1117-1129. doi: 10.1093/cvr/cvac171. Cardiovasc Res. 2023. PMID: 36534965 Free PMC article. Review. - How Carvedilol activates β2-adrenoceptors.
Benkel T, Zimmermann M, Zeiner J, Bravo S, Merten N, Lim VJY, Matthees ESF, Drube J, Miess-Tanneberg E, Malan D, Szpakowska M, Monteleone S, Grimes J, Koszegi Z, Lanoiselée Y, O'Brien S, Pavlaki N, Dobberstein N, Inoue A, Nikolaev V, Calebiro D, Chevigné A, Sasse P, Schulz S, Hoffmann C, Kolb P, Waldhoer M, Simon K, Gomeza J, Kostenis E. Benkel T, et al. Nat Commun. 2022 Nov 19;13(1):7109. doi: 10.1038/s41467-022-34765-w. Nat Commun. 2022. PMID: 36402762 Free PMC article. - β-Adrenergic Receptor Desensitization/Down-Regulation in Heart Failure: A Friend or Foe?
Mahmood A, Ahmed K, Zhang Y. Mahmood A, et al. Front Cardiovasc Med. 2022 Jul 1;9:925692. doi: 10.3389/fcvm.2022.925692. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35845057 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases